U.S. markets closed

  • S&P 500

    4,369.21
    -15.42 (-0.35%)
     

  • Dow 30

    34,888.79
    -107.39 (-0.31%)
     

  • Nasdaq

    14,677.65
    -55.59 (-0.38%)
     

  • Russell 2000

    2,238.86
    -42.96 (-1.88%)
     

  • Crude Oil

    75.21
    +1.11 (+1.50%)
     

  • Gold

    1,807.70
    +1.80 (+0.10%)
     

  • Silver

    26.06
    -0.18 (-0.68%)
     

  • EUR/USD

    1.1783
    -0.0084 (-0.71%)
     

  • 10-Yr Bond

    1.4150
    +0.0520 (+3.82%)
     

  • GBP/USD

    1.3813
    -0.0072 (-0.52%)
     

  • USD/JPY

    110.6080
    +0.2600 (+0.24%)
     

  • BTC-USD

    32,527.74
    -426.65 (-1.29%)
     

  • CMC Crypto 200

    785.12
    -23.61 (-2.92%)
     

  • FTSE 100

    7,124.72
    -0.70 (-0.01%)
     

  • Nikkei 225

    28,718.24
    +149.22 (+0.52%)
     

SANUWAVE Health Provides Updated Conference Call Information

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SUWANEE, GA / ACCESSWIRE / July 13, 2021 / SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation wound care products provided updated dial in instructions for its scheduled conference call on Thursday, July 15th at 4:30pm ET to discuss its recent business activity, provide an update on SEC filings and detail strategic initiatives.

Telephone access to the live call will be available by dialing the following numbers:

Toll Free: 844-407-9500
International: 862-298-0850

A replay of the call can be accessed through July 22, 2021 at:

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 42095

It is recommended that listeners call in at least 10 minutes prior to the start of the call.

About SANUWAVE Health
SANUWAVE Health (OTCQB:SNWV) is focused on the research, development, and commercialization of its patented, Energy First non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions. For more information, please visit. www.SANUWAVE.com.

Investor Relations Contact
Brian M. Prenoveau, CFA
Managing Director
MZ Group - MZ North America
(561) 489-5315
SNWV@mzgroup.us
www.mzgroup.us

SOURCE: SANUWAVE Health, Inc.



View source version on accesswire.com:
https://www.accesswire.com/655424/SANUWAVE-Health-Provides-Updated-Conference-Call-Information

Recommended Stories

  • Why Cassava Sciences Stock Moved Higher Monday

    Cassava stock actually went as high as $106.39 Monday before coming back to earth a bit at $99.32 at the close, but it was still 4.1% higher than it had been on Friday. The best explanation for Friday's drop was that the FDA's (Food and Drug Administration) acting head said the agency is asking the Office of the Inspector General to conduct a review regarding the FDA's decision to approve Aduhelm, an Alzheimer's treatment from Biogen, to see if any interactions between FDA staff and Biogen broke agency rules. While this doesn't have anything directly to do with Cassava, the company has its own Alzheimer's drug, Simufilam, in a phase 2 trial, and investors may have been concerned the agency would adopt stricter measures regarding other Alzheimer's treatment approvals moving forward.

  • Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO Study

    According to a study published in the Annals of Internal Medicine, neither Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) nor hydroxychloroquine (HCQ) did significantly clear the virus from hospitalized COVID-19 patients or affect the degree of respiratory failure and inflammation over the standard of care after ten days. Between 28 March and 4 October 2020, 185 patients were randomly assigned, and 181 were included in the full analysis set. Patients received remdesivir (n=42), HCQ (n

  • 3 Healthcare Stocks That Can Become Big-Time Alzheimer’s Players

    The recent approval of Biogen’s Alzheimer’s Disease (AD) drug Aduhelm (aducanumab) has signaled a seismic shift in the AD space. Prior to the go ahead from the regulators, no treatment that sought to address the underlying causes of the notoriously difficult to treat memory-wiping condition had ever been approved. However, following a negative AdCom and given slim chances of making the grade, the approval was highly controversial and sent shock waves across Wall Street. Still, it is somewhat of

  • Why the CDC and FDA Just Slapped Down Pfizer and Moderna

    Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). The FDA granted quick approvals to both drugmakers' COVID-19 vaccines last December. The CDC has encouraged Americans to receive both vaccines.

  • Investors Eyeing NovoCure’s Ovarian Cancer Treatment Trials

    The global oncology company NovoCure Ltd (NASDAQ: NVCR), which is focused on the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields), has been in the headlines lately. The company is striving to widen the survival of patients who have some of the most aggressive forms of cancer. Notably, the company is working on, or has completed, clinical trials related to TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, live

  • Is BMY Stock A Buy As Shares Surge On Promising Cancer Treatment Data?

    Is BMY stock a buy after Bristol Myers Squibb said a cancer drug called Breyanzi outperformed the standard treatment in patients with a form of lymphoma?

  • Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas

    (Bloomberg) -- Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resign

  • 3 Things About Invitae That Smart Investors Should Know

    Invitae (NYSE: NVTA) is on a mission "to bring comprehensive genetic information to mainstream medicine to improve healthcare for billions." In medical terms, Invitae can help the roughly one in six people who have a medical condition with an underlying genetic component. In financial terms, Invitae has the potential to generate several hundred dollars annually from more than 2 billion people -- a staggering market opportunity of $4 trillion.

  • US Medicare Starts Coverage Policy Review For Biogen's Aduhelm

    The U.S. government started a review process for national Medicare coverage of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm. The Centers for Medicare & Medicaid Services expects to give a proposed decision within six months and a final decision within nine months. Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged 65 and older. The review will include an analysis of published clinical studies and medica

  • BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks

    BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks patients. The HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo at the start of the trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Median attack rates also decreased from 2.7 attacks/month at

  • U.S. health official says COVID-19 boosters could risk more serious side effects

    (Reuters) -The United States is reviewing the need for a third COVID-19 booster shot among residents who have already been vaccinated but needs to see more data to know if additional shots could raise people's risk of serious side effects, a U.S. health official said Tuesday. The official said the second dose for two-shot COVID-19 vaccine regimens was associated with higher rates of side effects, suggesting a third dose could potentially come with even greater risks. "We're keenly interested in knowing whether or not a third dose may be associated with any higher risk of adverse reactions, particularly some of those more severe - although very rare - side effects," said Jay Butler, deputy director at the U.S. Centers for Disease Control and Prevention, during a media briefing.

  • Aging population to hit U.S. economy like a 'ton of bricks' - U.S. commerce secretary

    President Joe Biden does not yet have enough support from fellow Democrats to secure $400 billion in spending for at-home care for the elderly and disabled that the economy desperately needs, Commerce Secretary Gina Raimondo told Reuters on Monday. Raimondo, who is paying for round-the-clock care for her own 90-year-old mother, said America's aging demographics were going to hit the country "like a ton of bricks" without increased federal aid, and warned the current situation was "untenable." Failure to act, she said in an interview, would harm the U.S. economy by making it difficult for women - who fell out of the workforce by the millions during the COVID-19 pandemic - often to look after out-of-school children or parents - to return to work or remain in the workforce.

  • At 48, Heidi Klum Looks So Sculpted While Sunbathing Nude In New Instagram Photo

    Her hubby snapped the "HOT" pic.

  • 'We have rights': the French health workers furious about COVID vaccine order

    FONTENAY-AUX-ROSES, France (Reuters) - Nursing home worker Sandra Barona is so vehemently against receiving a COVID-19 shot that she said she may quit her job after French President Emmanuel Macron ordered all health workers to get vaccinated. Barona said Macron was discriminating between the vaccinated and unvaccinated - an issue some of Macron's opponents say could pose legal problems for the president's plans. Holding up the vaccine as the only path to leading a normal life, Macron said inoculation was a matter of individual responsibility but also a matter of collective freedom as the Delta variant spurs the rapid spread of new infections.

  • Nightclubs could be forced to ask customers for vaccine ‘passports’, government warns

    Boris Johnson has announced that the planned 19 July unlocking in England will go ahead.

  • Psychedelics M&A: Wesana Health To Purchase PsyTech In $17M All-Stock Transaction

    On Tuesday, Wesana Health Holdings (CSE: WESA), a life science company that champions the development of psychedelics and other medicines for the treatment of traumatic brain injury, announced a definitive agreement to acquire PsyTech Inc. in an all-stock transaction for approximately CA$21 million ($16.8 million). “The acquisition of PsyTech will greatly accelerate our ability to understand, analyze and improve neurological health and performance by providing a data platform on which to build o

  • Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence

    Retrospective Study of Veterans Health Administration Data Showed an Association Between VIVITROL Treatment and Reduced Emergency Department Visits and Inpatient Hospital Stays

  • Boy, 3, dies after being sedated for routine operation at dentist

    He died after about ‘30 minutes of being sedated’ with anaesthesia

  • Why Moderna Stock Rose Today

    What happened Shares of Moderna (NASDAQ: MRNA) climbed 3% on Monday following reports that Food and Drug Administration officials are considering a new safety warning for Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.

  • Doping-USADA wants fair cannabis rules as White House calls for meeting

    The United States Anti-Doping Agency (USADA) says it wants more flexible rules for athletes who test positive for cannabis after the White House was reported to be seeking a meeting with the World Anti-Doping Agency (WADA) to discuss easing restrictions. The suspension sparked an outpouring of sympathy, including from President Joe Biden, and calls for a review of anti-doping rules from the White House according to the Financial Times. The White House did not respond to a request for comment.